Merck restructures its Human Health business as Keytruda faces a 2028 patent loss.
Merck & Co. Inc. (NYSE:MRK) shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execution across various therapeutic areas.
This strategic move comes as broader markets experi… [2648 chars]
Source: Benzinga | Published: 2026-02-23T14:16:11Z
Credit: Benzinga
